Elixir Medical announced four-year results from a study comparing its DynamX coronary bioadaptor system to a leading drug-eluting stent.
Significantly lower TLF rates (2.8% versus 7.8%, p=0.020) with DynamX® compared to Resolute Onyx DES with no new events in bioadaptor arm between 3 and 4 years 88% reduction in Cardiovascular Death (0 ...
Elixir Medical Corp. reported four-year data from the Bioadaptor randomized controlled trial presented at the EuroPCR conference in Paris, which showed that patients with coronary artery disease ...
Coronary stents were first developed in the mid 1980s, revolutionizing coronary artery disease treatment for patients. While stents are still used in patients today, only incremental developments in ...
DynamX® bioadaptor is the first interventional technology to demonstrate significant benefit with a reduction in long term adverse events in two consecutive randomized controlled trials MILPITAS, ...
Cardiovascular disease affects 315 million people globally and is the world’s leading cause of death. For the past quarter-century, it has been standard practice for heart surgeons to treat this by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results